Good day,
We are excited to introduce you to a new way to receive The Early Bird's "Stock of the Day" a day before the stock idea shows up in The Early Bird's email newsletter.
Our free "Stock of the Day" service is delivered via SMS so that you can see each stock pick right away.
Each morning, you'll receive:
- Actionable stock picks, hand selected by MarketBeat's team of expert research analysts.
- Headlines and market insights for each selected ticker.
- A bull case and a bear case to help inform your next move.
- Timely updates and alerts so that you can capitalize quickly on each opportunity.
Ready to take your investing and trading to the next level?
Click Here to Receive The Early Bird's Stock of the Day (Free)
Best regards,
The Early Bird Team
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
Authored by Nathan Reiff. Publication Date: 3/12/2026.
Key Points
- Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon's "Hidden" Company
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Many companies take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, several promising treatments have shown significant potential—and with that comes the possibility of sizeable sales.
Two smaller biotech companies are seeing notable share-price momentum thanks to their leading oncology drugs. Besides offering strong therapeutic potential, these medicines could help the firms move beyond penny-stock (or otherwise unstable) status and toward long-term profitability. Both remain high-risk investments, but they also carry the potential for outsized rewards for investors willing to take a chance.
Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
Click here to get the details and I'll show you how to claim your stake…Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% during a week when the S&P 500 fell roughly 1%. The rally helped IOVA more than double year-to-date (YTD). Still, with a consensus price target of $8.88, Wall Street expects more from the stock—that target implies about 71% upside from current levels.
The primary catalyst for Iovance's move is its lead therapy, Amtagvi, a T-cell immunotherapy for certain types of melanoma.
Amtagvi has been approved in the United States since 2024 and is gaining traction, with additional approvals likely in the E.U., U.K., and elsewhere. When used with Proleukin, Iovance's IL-2 immunotherapy, management projects U.S. peak sales above $1 billion.
Its broader upside may lie outside melanoma: Amtagvi received FDA Fast Track designation for non-small cell lung cancer and may be effective against other tumor types.
Iovance's outperformance was also supported by its Q4 2025 earnings report, released in late February, which showed smaller-than-expected losses per share and $5 million in revenue. For the full year, revenue rose roughly 30% year-over-year.
Iovance is a small-cap (about $2 billion) biotech and, despite the rally, remains a penny stock; analysts remain cautious—about half of its roughly dozen ratings are Hold or Sell. Risks are elevated: beyond the typical uncertainties facing smaller biotechs, Amtagvi is a personalized therapy that is costly and complex to manufacture, which could constrain margins and slow the firm's path to profitability even as demand grows.
Massive Sales Growth for ImmunityBio's Bladder Cancer Drug
ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its YTD performance dwarfs Iovance's. IBRX shares are up nearly 300% in 2026 alone, and this may be only the beginning. Analysts' consensus target of $13.60 implies roughly 70% upside from current levels.
ImmunityBio's primary growth driver is Anktiva, a treatment for specific types of bladder cancer. In February, shares spiked after the E.U. regulator granted the drug conditional marketing authorization, the latest in a string of approvals worldwide.
Anktiva drove $113 million in sales last year, roughly a 700% year-over-year increase.
Like Amtagvi, Anktiva may have potential in additional cancer indications, and ImmunityBio is actively exploring those possibilities.
Despite the surge over recent quarters, IBRX remains a speculative and risky investment. The company posted a full-year net loss of $351 million for 2025 as R&D expenses continue to mount. Still, Wall Street appears somewhat more optimistic on ImmunityBio than on Iovance: six of seven analysts rate the shares a Buy or equivalent.
Alphabet's Pullback May Be Opening a New Entry Point
Authored by Ryan Hasson. Publication Date: 3/11/2026.
Key Points
- GOOGL shares have pulled back more than 12% from recent highs but appear to be stabilizing near the key $300 support level.
- Strong institutional demand continues to support the stock, with roughly $164 billion in inflows over the past 12 months.
- Analysts remain bullish, with a Moderate Buy consensus rating and a price target implying nearly 20% upside from current levels.
- Special Report: Elon's "Hidden" Company
Technology giant Alphabet (NASDAQ: GOOGL) has confirmed a major support level on a higher time frame, potentially creating a fresh entry opportunity for long-term investors.
The Magnificent Seven standout — still up roughly 77% over the past year — has pulled back more than 12% from its recent record highs. Much of the decline has come alongside a broader technology sector selloff that was further exacerbated by rising geopolitical tensions in the Middle East.
Silver paying 20% dividend. Plus 68% share gains (Ad)
Silver Is Now a Growth AND Income Play
For decades, silver paid nothing. That just changed. One tiny ETF is delivering 20% annualized distributions plus 68% share appreciation in just 5 months.
Click here to learn more about this fund.Importantly, little has changed fundamentally for Alphabet. The company remains dominant across global search, digital advertising and artificial intelligence. While the long-term fundamental story remains intact, the recent pullback has shifted focus to the technical picture, where the stock may now be setting up for its next move higher.
GOOGL Finds Support Near Key $300 Level
From a technical perspective, Alphabet's recent pullback appears to be stabilizing near a critical support zone.
After retreating from its February all-time high, the stock found support around the $300 level. That area has already proved significant, acting as support in both mid-December and mid-March.
On Monday, March 9, shares briefly dipped below $300 intraday before quickly recovering with the broader market and closing above $306. That rebound reinforces the idea that buyers are defending the level, helping to confirm $300 as an important line in the sand for the stock in the short term.
If Alphabet can push back above its 20-day simple moving average and then reclaim the 50-day moving average, it would form a higher low. That structure would keep the broader uptrend intact and suggest the recent pullback was a reset within a longer-term bullish trend.
The correction has also improved the company's valuation profile.
When shares traded near their all-time highs, Alphabet's forward price-to-earnings ratio had moved well above its historical average. After the double-digit pullback, the stock now trades closer to a forward P/E of roughly 22.
For a dominant technology company that continues to deliver strong growth across search, cloud and AI, that valuation looks materially more reasonable.
Institutional Demand Continues to Climb
Another key indicator investors watch is institutional ownership: steady increases often signal that large funds and asset managers are accumulating shares with longer investment horizons, reinforcing demand for the stock.
Alphabet currently has institutional ownership of about 40%, and that figure has risen meaningfully over the past year. Over the last 12 months, institutional investors recorded roughly $164 billion in inflows versus about $82 billion in outflows, highlighting a strong net accumulation even as the stock rallied.
Short-term flows tell a similar story. In the fourth quarter of 2025, Alphabet saw $78 billion in inflows compared with $33 billion in outflows, a substantial net inflow that suggests large investors continued to build positions during periods of market volatility.
Analysts Continue to See Meaningful Upside
Institutional sentiment is often supported by analyst coverage and optimism. Alphabet is currently covered by 51 analysts, making it one of the most widely followed stocks in the market.
Of those analysts, 46 rate the stock a Buy, producing an overall Moderate Buy consensus rating.
The average analyst price target sits around $367.18, implying nearly 20% upside from current levels. If shares reached that level, it would represent a new all-time high for the stock.
Most recently, on March 6, analysts at Robert W. Baird raised their price target on Alphabet from $375 to $380, a forecast that implied more than 26% potential upside at the time.
The upgrade was driven largely by Alphabet's strong fourth-quarter 2025 results and continued momentum in its cloud and artificial intelligence segments, both of which remain key long-term growth drivers.
A Reset Within a Long-Term Uptrend
While short-term volatility has weighed on many technology stocks recently, Alphabet's broader outlook remains largely unchanged.
The pullback toward the $300 support level has allowed the stock to reset technically and improve its valuation. At the same time, institutional inflows and solid analyst sentiment suggest confidence in the company's long-term trajectory remains intact.
If the stock can continue holding support and reclaim key moving averages in the weeks ahead, this dip may ultimately prove to be another buying opportunity within Alphabet's longer-term uptrend.
This email message is a paid advertisement provided by The Early Bird, a third-party advertiser of MarketBeat. Why did I receive this email message?.
If you need assistance with your account, please contact our U.S. based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Pl. #620, Sioux Falls, South Dakota 57103-7078. United States of America..